Recent Stories
American Biotech — The Future Can’t Be Won Without It.RSI is AI Building AI. What DC needs to know about it. Keeping the Human in Medicine: Two AI CoLab Researchers on What Machines Can’t ReplaceSomeone Is Hacking the Freezers. Pay Attention.Thinking of Running in 2028? Start HereWhat the Lame Duck Session Has to Do With the Ultimate 21st-Century Power Tool: Robots

American Biotech — The Future Can’t Be Won Without It.

China now out-innovates and out-supplies America in drug ingredients and trials — the fix requires rethinking pricing, coverage, and production at home.

Manufacturing image
credit: Précis AI
Key takeaways3
  • Drugmakers have pledged over $500 billion in U.S. investment, including about 22 new sites and 44,000 announced jobs.
  • China controls up to 94% of key starting materials for drugs like amoxicillin, 74% for heparin, and 70% for acetaminophen, per a CFR report.
  • Louisiana's subscription-pricing model for hepatitis C drugs turned $37 million in spending into $266 million in medical savings over five years.

Innovating and making medicines in the U.S. is a national priority, and so is making sure Americans can afford them. Getting both right means demanding new ideas.

Advances in technology are giving America’s health future unbelievable prospects: faster discovery, smarter factories, treatments that catch disease before it becomes expensive and dangerous. They will also challenge some of our most basic ideas about fairness and equality, because the people who can afford those advances and the people who can’t could end up living very different lives.

Finding our way through, will take Americans challenging the false choices of the old conversation and demanding new ideas, not retreads of the argument we’ve been having for 50 years. Two things are true at once.

First, the ability to develop and make drugs here is non-negotiable. We will either find that out the easy way or the hard way. Some lessons the country learns ahead of time. Others, like keeping box cutters off airplanes, it learns after the damage is done. This one should be a national priority, for four reasons:

  • Security. A country that can’t make its own medicines can have its supply used as leverage, as the next section shows.

  • Fiscal health. As the population ages, the cost of care keeps growing. Medicines that prevent expensive hospital care later are one of the few ways to bend that curve.

  • Jobs. Drugmakers’ pledges to build here, more than $500 billion,[1] include about 22 new sites and 44,000 announced jobs.[2]

  • Basic decency. A person’s access to a lifesaving drug shouldn’t depend on a dispute between two governments.

Second, everyone will lose if we let society divide further into people who can afford their health and people who can’t.

Technology can help us find a new way, and Dr. Leroy Hood, the biologist who co-founded the Institute for Systems Biology, has done more than most to show what it looks like: what he calls scientific wellness, a health system built around keeping people well, not just treating them once they’re sick. Getting there will also take work from every side. We should challenge politicians to find a new way of thinking and talking about American wellness, and reward them when they do. The industry will have to rethink how it operates, how it prices, and how it explains both. And insurers and the benefit managers who work for them, who largely decide which treatments are covered and what patients pay, will have to cover breakthrough medicines in ways that reflect what they save, and be open about how prices are set. The idea that can guide all of them is simple: America leading the world, by innovating and producing the medicine it needs, is a national security issue, a fiscal issue, and a moral one.

The Ingredient Problem

Imagine your child is sick, and the pharmacist tells you the antibiotic the doctor prescribed isn’t available. Or imagine a family member is in the hospital and needs a blood thinner like heparin, and the hospital is rationing it. You ask why. The answer isn’t a hurricane or a factory fire. It’s a dispute between two governments, and the chemical building blocks come from China, which has slowed its exports.

That hasn’t happened. But the people who study America’s drug supply say the lever exists, and that we’ve built the conditions for it.

Most Americans have never heard of “key starting materials,” the chemical building blocks of generic drugs. They matter a great deal. A June report from the Council on Foreign Relations argues that the U.S. drug supply chain faces a threat equal to the rare-earths challenge[3] China already poses in critical minerals. As summarized by one outlet, the report finds China controls 94 percent[4] of the starting materials for amoxicillin, 74 percent of the heparin supply, and 70 percent of acetaminophen. Direct imports understate the exposure, because India’s generics industry gets 70 to 85 percent[5] of its ingredient intermediates from China.

Others have reached similar conclusions. A congressional advisory body, the U.S.-China Economic and Security Review Commission, has examined China’s ability and willingness to weaponize[6] its position in pharmaceutical supply chains. The Atlantic Council notes that a third of generic active ingredients come from sole suppliers,[7] many in China.

Two cautions. Estimates of U.S. reliance range from 8 to 47 percent[8] depending on how it’s measured. And none of these sources says China has cut off supply. The risk is a lever, not an event.

The Innovation Race

China is no longer just a supplier. Chinese companies developed 46 percent[9] of the drug candidates entering human trials for the first time in the first half of 2025, according to Goldman Sachs, up from about 17 percent a decade earlier. Licensing of Chinese-origin drugs reached $137.7 billion[10] in 2025. A federal biotechnology commission said China rose from near irrelevance to dominance[11] in three years. And early-stage trials are now faster and cheaper[12] there than here.

Innovation That Pays for Itself

There’s a way of seeing biotech research that rarely makes the price debate: the best medicines don’t just treat illness, they prevent the expensive care that comes later.

Hepatitis C is the clearest example. The cure arrived in 2013 at a steep price, and many states rationed it. In 2019, Louisiana tried a “Netflix” model, paying a fixed fee for unlimited access to the drugs. According to an NBER working paper[13] that hasn’t yet been peer reviewed, the state’s $37 million in added antiviral spending produced $266 million in medical savings over five years, and four times as many Medicaid patients[14] were treated. An earlier study[15] found liver transplants in the state fell 27 percent.

Federal scorekeepers see a version of this too. Since 2012, the Congressional Budget Office has counted an offset [16]: when Medicare enrollees fill more prescriptions, spending on hospital and doctor care goes down.

RelatedRSI is AI Building AI. What DC needs to know about it. Anthropic's SEC filing and a METR audit show AI-driven research speeding up roughly 1.9x, fueling bipartisan calls to ban recursive self-improvement.Holly PageHolly Page··4 min read

It doesn’t work for every drug. Savings can take years and show up in a different part of the system than the cost, as the CBO’s split between Medicare’s drug coverage and its hospital and doctor coverage shows. Insurers face the same puzzle: the plan that pays for a cure isn’t always the one that saves on the transplant years later. And it depends on design: Washington state’s subscription program had little effect[17], likely because its coverage was already generous. But it suggests a better question than “what does this drug cost?” It’s “what does it save, and how do we pay for it out of the savings?”

Why This Matters to Deficit Hawks

For anyone focused on the deficit, the arithmetic is hard to avoid. The Congressional Budget Office projects that federal spending will rise from 23.1 percent of the economy in 2025 to 24.4 percent by 2036, largely driven[18] by Social Security, health care programs, veterans’ spending, and interest on the debt. Medicare’s hospital trust fund is estimated to run dry around 2040[18]. A serious plan for the deficit has to reckon with how fast health costs are growing, and that includes Medicare. That is not an argument against innovation. It’s an argument for the kind that keeps people healthier longer and gets sick people treated earlier, because that is one of the few ways to slow the growth in what the country spends.

Not Black and White

Affordable medicines and strong innovation can seem to pull in opposite directions. Roughly 90 percent of drug candidates fail in clinical trials[19], and the cost of those failures is built into the price of the drugs that succeed. Making medicines at home and keeping them affordable can seem to pull apart, too.

Technology, from AI to robots, may offer a way through.

  • Smarter research. An early analysis found AI-discovered drugs clearing Phase 1 trials at 80 to 90 percent[20], well above the historical rate. Phase 2, the harder test, was about 40 percent, close to the historical average, and the sample is small. The jury is still out.

  • Smarter, more automated factories. Continuous manufacturing runs compact, automated lines instead of stop-and-start batches, and robots are moving onto the plant floor. Robot orders in life sciences and pharma rose 22 percent[21] in the second quarter of 2025, the fastest of any sector that quarter, according to the industry’s trade association, as companies cope with labor shortages, reshoring, and strict rules on sterile manufacturing. FDA says it has approved 17 drugs[22] using continuous manufacturing, and its FRAME initiative[23] is preparing a regulatory framework for such technologies, including AI. One manufacturing executive argues that copying the batch plants of China and India won’t be competitive[24]: “The way to compete is by reshoring with innovation.”

  • What it doesn’t solve. Plants are expensive to retrofit, regulators have to keep up, and cheaper production only means cheaper medicine if competition or pricing rules pass the savings on.

Technology doesn’t settle the argument. It changes what’s possible, which is the point.

What We’ve Started, and What’s Missing

To date, Washington’s response to the supply-chain and innovation challenge has been real. The BIOSECURE Act was part of the FY2026 defense bill[25], and companies are pledging factories. But the gaps are in the less visible places. Most factory pledges are spread over four to ten years [1], and some are tied to tariff relief. Congress rejected a proposed 41 percent NIH cut [26], yet fewer grants are being awarded[27], which affects the scientists of the next decade. The industry’s trade group put it plainly[10]: “We cannot restrict our way to success.”

A New Congress, an Old Question

In January, Democrats take control of the House and the Senate. The open question is who will lead a different conversation: one that rejects the false choice between lower prices and more innovation, and points toward a future where innovation is how prices come down, instead of the thing we give up to lower them.

What Winning Looks Like

The goal is capability, not blame:

  • Use innovation to bring prices down, by lowering the cost of research and manufacturing and passing the savings to patients, and to keep America the leader in an industry it pioneered.

  • Move toward prevention and early detection, and away from the expensive treatments and procedures that come when illness is caught late.

  • Judge a medicine’s price by what it saves, counting the future costs avoided when disease is found and treated early.

  • Make the ingredients, not just the pills, with enough supply to ride out a disruption.

  • Run early trials here, faster and at lower cost.

  • Keep the science engine steady, including the young researchers behind the next breakthroughs.

  • Back early-stage companies with patient capital.

  • Work with partners, with guardrails, protecting data and security without cutting off science that helps patients.

Questions for Washington

  • Which medicines and ingredients are critical enough to need a guaranteed supply?

  • What would make the U.S. the fastest, best place to run an early trial?

  • How do we keep factories here after the tariff deadlines pass?

  • How do we pay for breakthrough medicines out of the savings they create, across programs and over years?

  • How do we slow the growth of Medicare costs by keeping people healthier, not only by paying less for care?

  • What role should insurers and benefit managers play, in covering new treatments and in being open about prices?

  • How do we make sure an already burdened public doesn’t carry more than its share of the transition costs, while giving people a real stake in the bigger change that scientific wellness offers?

Frequently asked questions

How much of America's generic drug ingredients come from China?

China controls about 94 percent of starting materials for amoxicillin, 74 percent of heparin supply, and 70 percent of acetaminophen, according to a Council on Foreign Relations report. Indian generics makers, which supply much of the U.S. market, also get 70 to 85 percent of their ingredient intermediates from China.

What is the BIOSECURE Act and how does it address biotech security?

The BIOSECURE Act, included in the FY2026 defense bill, is part of Washington's response to supply-chain risks and the innovation race with China. It accompanies industry pledges of more than 500 billion dollars in U.S. factory investment, though most pledges are spread over four to ten years and some depend on tariff relief.

How is China competing with the U.S. in drug innovation?

Chinese companies developed 46 percent of new drug candidates entering first-in-human trials in early 2025, up from about 17 percent a decade earlier, according to Goldman Sachs. Licensing of Chinese-origin drugs reached 137.7 billion dollars in 2025, and a federal biotech commission said China went from near irrelevance to dominance in three years.

Can new medicines actually lower overall healthcare costs?

Yes, some medicines prevent expensive later care, as shown by Louisiana's 2019 hepatitis C subscription model. The program added 37 million dollars in drug spending but produced 266 million dollars in medical savings over five years while treating four times as many Medicaid patients, per an NBER working paper.

Why does Medicare's financial outlook matter to the biotech debate?

Medicare's hospital trust fund is projected to run dry around 2040, and federal spending is expected to rise from 23.1 percent of the economy in 2025 to 24.4 percent by 2036, largely due to health programs. The article argues innovation that keeps people healthier longer, rather than cheaper short-term drug pricing alone, is key to slowing that cost growth.

References

  1. [1]Aranca, "Built to Deadline: Why Pharma's US Factory Pledges May Not Outlast the Tariffs that Prompted Them" (Nov. 5, 2026). Supports the pledge total of more than $500 billion. https://www.aranca.com/knowledge-library/articles/business-research/pharma-us-manufacturing-pledges
  2. [2]Packaging Digest, "The Great Pharma Reshoring Wave" (Nov. 2026), citing The World Data. About 22 new sites and 44,000 jobs, as announced.
  3. [3]Council on Foreign Relations, "New CFR Report Outlines How the U.S. Can Reduce Its Pharmaceutical Dependence on China" (June 2026). Full report: Bollyky et al., "The Pharma Choke Point," https://www.cfr.org/reports/the-pharma-choke-point
  4. [4]MedPath, "CFR Report Warns U.S. Pharmaceutical Supply Chain Faces 'Rare Earths'-Level Threat from Chinese Dependence" (June 2026). Secondary summary of the CFR figures.
  5. [5]CIRSD, "A Biopharmaceutical Superpower: China's Rise, Its Limits, and What Comes Next" (2026).
  6. [6]U.S.-China Economic and Security Review Commission, 2025 Annual Report to Congress, Chapter 9, "Chained to China: Beijing's Weaponization of Supply Chains" (Nov. 2025).
  7. [7]Atlantic Council, "Pharmaceuticals are China's next trade weapon" (Econographics).
  8. [8]Pharmaceutical Commerce, "How China Turned US Trade Compliance Into a Supply Chain Risk" (June 26, 2026), citing Brookings.
  9. [9]Asia Business Daily, "U.S. Clamps Down on China Biotech Investment… Dilemma Over New Drug Collaboration" (Oct. 27, 2026), citing Goldman Sachs.
  10. [10]Asia Times, "The US-China biotech trade war that isn't" (Oct. 2026).
  11. [11]FirstWord Pharma, "Report warns China drug innovation fastech" (Dec. 19, 2025), on a paper from the National Security Commission on Emerging Biotechnology. https://firstwordpharma
  12. [12]Axios, "China threatens U.S.' drug-making crown amid Truml" (Jan. 30, 2026).
  13. [13]Callison, Conti, Gruber, and Wallace, "Spending to Save: Eradicating Hepatitis C in Louisiana," NBER Working Paper35583 (2026), not peer reviewed. Reports $37 million in incremental spending and $266 million in five-year savings.
  14. [14]Employer Coverage, "Subscription model for Hepatitis C medications lowered medical costs in Louisiana" (Aug. 20, 2026). Secondary summary of the same research; source for the fourfold increase in patients trecline in new diagnoses.https://employercoverage.substack.com/p/subscription-model-for-hepatitis
  15. [15]NBER Working Paper 33617, on the effects of Louisiana's Hn on liver transplants (27 percent reduction).
  16. [16]Congressional Budget Office, "Offsetting Effects of Prescre's Spending for Other Health Care Services" (Nov. 2012). https://www.cbo.gov/sites/default/files/cbofiles/attachments/412.pdf CBO's later estimates apply the offset to Medicare Parts A and B (for example, https://www.cbo.gov/system/files/2023-02.
  17. [17]STAT, "Subscription pricing could expand access to HIV prevention breakthrough while controlling costs" (April 3, 2026). Notes minimal effect in Washington state.
  18. [18]Committee for a Responsible Federal Budget, "CBO's February 2026 Budget and Economic Outlook." The 2040 trust-fund date is CRFB's estimate under CBO's baseline. https://www.crfb.org/papers/cbos-february-2026ok
  19. [19]bioRxiv preprint (Oct. 2025) on drug development failure also the source for the commonly cited $2.3 billion cost per approved drug. https://www.biorxiv.org/content/10.1101/2025.10
  20. [20]Levin, "How successful are AI-discovered drugs in clinica, summarizing a published analysis. Other analyses report lower Phase 2 rates. https://garymarklevin.substack.com/p/how-succes
  21. [21]Pharma Manufacturing, "Robot orders in life sciences, phaor operational efficiency" (Aug. 13, 2025), citing theAssociation for Advancing Automation (A3). https://www.pharmamanufacturing.com/all-articles/article/55309458/robot-orders-in-life-sciences-pharma-up
  22. [22]Regulatory Focus (RAPS), "FDA official: 17 drugs approveduring, growth seen in emerging tech program" (May 20, 2026).https://www.raps.org/resource/fda-official-17-drugs-approved-using-continuous-manufacturing-growth-seen-i
  23. [23]FDA CDER, "Framework for Regulatory Advanced Manufacturinative."https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/cders-framework-regulatory-advance
  24. [24]Healthcare Dive, "The Trump administration wants to onshohnologists are answering the call" (July 9, 2025); quote fromSalvatore Mascia, CEO of Continuus Pharmaceuticals. https://www.healthcaredive.com/news/trump-administration-wantsufacturing-technologists/751025/
  25. [25]Pharmaceutical Technology (GlobalData), "Pharma positionsvolving US landscape," via Yahoo Finance.https://finance.yahoo.com/news/pharma-positions-itself-2026-am
  26. [26]NPR, "These 6 charts show how NIH research funding has beSept. 24, 2026).https://www.npr.org/2026/09/24/nx-s1-5931971/trump-nih-sciences
  27. [27]Drug Discovery News, "The NIH funding crisis that could ro come" (2026).

Suggested

Analytics cookies help us see how the site is used. They only run if you accept. Privacy Policy